Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Jun
15
Today In Oncology
Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors
Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Diagnostic Accuracy of Navigational Bronchoscopy vs Transthoracic Needle Biopsy in Lung Nodules
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo